YPI 011
Alternative Names: YPI-011Latest Information Update: 28 Feb 2024
At a glance
- Originator Yungjin Pharm Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastro-oesophageal reflux
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux(In volunteers) in South Korea (PO, Tablet)
- 14 Jun 2021 Yungjin Pharm. Co. and Seoul National University Hospital completes phase I trial in Gastro-oesophageal reflux (In volunteers) in South Korea (PO) (NCT04703868)
- 13 Jan 2021 Phase-I clinical trials in Gastro-oesophageal reflux (In volunteers) in South Korea (PO) (NCT04703868)